Inmune Bio, Inc. | Business Contracts

Amendment No. 2 to Rights Agreement, dated as of December 9, 2022, between the Company and VStock Transfer LLC, as Rights Agent (Filed With SEC on December 12, 2022)

Form of Securities Purchase Agreement (Filed With SEC on March 24, 2022)

Lease Agreement dated September 13, 2021 (Filed With SEC on September 15, 2021)

Form of Placement Agency Agreement (Filed With SEC on July 15, 2021)

First Amendment to License Agreement (Filed With SEC on June 15, 2021)

INmune Bio, Inc. 2021 Stock Incentive Plan (Filed With SEC on June 3, 2021)

Form of Option Agreement for Employees of the Company (Filed With SEC on March 24, 2022)

Form of Option Agreement between the Company and Non-Employee Directors and consultants (Filed With SEC on March 24, 2022)

Description of Securities of INmune Bio, Inc (Filed With SEC on March 3, 2022)

Amendment No. 1 to Rights Agreement, dated as of December 20, 2021, between INmune Bio Inc. and Vstock Transfer, LLC (Filed With SEC on December 21, 2021)

Form of Securities Purchase Agreement (Filed With SEC on July 15, 2021)

Form of Option Agreement for Employees of the Company (Filed With SEC on June 24, 2021)

Form of Option Agreement between the Company and Non-Employee Directors (Filed With SEC on June 24, 2021)

Warrant to Purchase Common Stock issued to Silicon Valley Bank (Filed With SEC on June 15, 2021)

Warrant to Purchase Common Stock issued to SVB Innovation Credit Fund VIII, L.P (Filed With SEC on June 15, 2021)

Loan and Security Agreement (Filed With SEC on June 15, 2021)

Option Cancellation Agreement between INmune Bio Inc. and Xencor, Inc (Filed With SEC on June 15, 2021)

Form of agreement between INmune Bio Inc. and National Securities Corporation, dated March 29, 2021 (Filed With SEC on March 29, 2021)

At-The-Market Sales Agreement, dated March 10, 2021, between the Company and BTIG (Filed With SEC on March 11, 2021)

Employment Agreement effective as of January 1, 2021 between INmune Bio Inc. and David Moss (attached hereto) (Filed With SEC on March 4, 2021)

Employment Agreement effective as of January 1, 2021 between INmune Bio Inc. and Raymond J. Tesi (attached hereto) (Filed With SEC on March 4, 2021)

Rights Agreement, dated as of December 30, 2020, by and between INmune Bio Inc. and VStock Transfer, LLC (Filed With SEC on January 4, 2021)

Rights Agreement, dated as of December 30, 2020, by and between INmune Bio Inc. and VStock Transfer, LLC (Filed With SEC on December 30, 2020)

Amendment to Exclusive License Agreement (Filed With SEC on November 5, 2020)

Amendment No. 1 to At-The-Market Sales Agreement, dated April 16, 2020, between the Company and BTIG (Filed With SEC on August 19, 2020)

Underwriting Agreement, dated July 16, 2020, by and between INmune Bio, Inc. and BTIG, Inc., as representative of the underwriters named therein (Filed With SEC on July 16, 2020)

At-The-Market Sales Agreement, dated April 16, 2020, between the Company and BTIG (Filed With SEC on April 17, 2020)

INmune Bio, Inc. 2019 Stock Incentive Plan (attached hereto) (Filed With SEC on March 11, 2020)

Award Agreement dated as of February 4, 2020 (Filed With SEC on February 10, 2020)

Common Stock Repurchase Agreement (Filed With SEC on January 27, 2020)

Amendment No. 2 to Securities Purchase Agreement between INmune Bio, Inc. and Raymond J. Tesi (Filed With SEC on May 24, 2019)

Amendment to Securities Purchase Agreement between INmune Bio, Inc. and David J. Moss (Filed With SEC on May 17, 2019)

Amendment to Securities Purchase Agreement between INmune Bio, Inc. and Raymond J. Tesi (Filed With SEC on May 17, 2019)

Registration Rights Agreement between INmune Bio Inc. and Lincoln Park Capital Fund, LLC, dated May 15, 2019 (Filed With SEC on May 16, 2019)

Purchase Agreement between INmune Bio Inc. and Lincoln Park Capital Fund, LLC, dated May 15, 2019 (Filed With SEC on May 16, 2019)

Award Letter dated as of February 22, 2019 from the Alzheimers Association to INmune Bio, Inc (Filed With SEC on February 28, 2019)

Inmune Bio, Inc. (36)